Literature DB >> 30536829

Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease.

Helena Bejr-Kasem1,2,3,4, Javier Pagonabarraga1,2,3,4, Saül Martínez-Horta1,2,3,4, Frederic Sampedro3,4, Juan Marín-Lahoz1,2,3,4, Andrea Horta-Barba1,3,4, Ignacio Aracil-Bolaños1,3,4, Jesús Pérez-Pérez1,3,4, M Ángeles Botí1,3,4, Antonia Campolongo1,3,4, Cristina Izquierdo1,3,4, Berta Pascual-Sedano1,2,3,4, Beatriz Gómez-Ansón2,3,5, Jaime Kulisevsky1,2,3,4.   

Abstract

BACKGROUND: Minor hallucinations and well-structured hallucinations are considered in the severity continuum of the psychotic spectrum associated with Parkinson's disease. Although their chronological relationship is largely unknown, the spatial patterns of brain atrophy in these 2 forms of hallucinations partially overlap, suggesting they share similar pathophysiological processes. Functional connectivity studies show that disruption of functional networks involved in perception and attention could be relevant in the emergence of well-structured hallucinations. However, functional neuroimaging studies in patients with isolated minor hallucinations are lacking. The objectives of this study were to explore the structural and functional changes underlying minor hallucinations.
METHODS: We compared patients with (n = 18) and without (n = 14) minor hallucinations using a multimodal structural (gray-matter volume voxel-based morphometry) and functional (seed-to-whole-brain resting-state functional MRI) neuroimaging study.
RESULTS: Coincident with previously described structural changes in well-structured hallucinations in Parkinson's disease, patients with minor hallucinations exhibited gray-matter atrophy with significant voxel-wise differences in visuoperceptual processing areas and core regions of the default mode network. Functional connectivity changes consisted of altered connectivity within the default mode network, reduced negative correlation with task-positive network, and aberrant connectivity between posterior regions of the default mode network and visual-processing areas. These changes are in accordance with the attentional networks hypothesis proposed for well-structured hallucinations.
CONCLUSIONS: Although longitudinal studies are needed to assess the potential role of minor hallucinations as an early clinical biomarker of progression to well-structured hallucinations, the present findings show that the 2 phenomena share similar structural and functional brain correlates.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; attentional networks; default mode network; functional neuroimaging; minor hallucinations

Year:  2018        PMID: 30536829     DOI: 10.1002/mds.27557

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

Review 1.  Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications.

Authors:  Abhishek Lenka; Javier Pagonabarraga; Pramod Kumar Pal; Helena Bejr-Kasem; Jaime Kulisvesky
Journal:  Neurology       Date:  2019-07-09       Impact factor: 9.910

Review 2.  Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction.

Authors:  Marco Onofrj; Alberto J Espay; Laura Bonanni; Stefano Delli Pizzi; Stefano L Sensi
Journal:  Mov Disord       Date:  2019-07-15       Impact factor: 10.338

3.  Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment.

Authors:  Frederic Sampedro; Juan Marín-Lahoz; Ignacio Aracil-Bolaños; Andrea Horta-Barba; Saül Martínez-Horta; José María Gónzalez-de-Echávarri; Jesús Pérez-Pérez; Helena Bejr-Kasem; Berta Pascual-Sedano; Mariángeles Botí; Antonia Campolongo; Cristina Izquierdo; Alexandre Gironell; Beatriz Gómez-Ansón; Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Brain Imaging Behav       Date:  2021-09-22       Impact factor: 3.978

Review 4.  Functional Connectome in Parkinson's Disease and Parkinsonism.

Authors:  Sule Tinaz
Journal:  Curr Neurol Neurosci Rep       Date:  2021-04-04       Impact factor: 5.081

Review 5.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

Review 6.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

7.  Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson's Disease.

Authors:  Min Zhong; Ruxin Gu; Sha Zhu; Yu Bai; Zhuang Wu; Xu Jiang; Bo Shen; Jun Zhu; Yang Pan; Jun Yan; Li Zhang
Journal:  Behav Neurol       Date:  2021-10-04       Impact factor: 3.342

8.  Deep Brain Stimulation Modulates Multiple Abnormal Resting-State Network Connectivity in Patients With Parkinson's Disease.

Authors:  Yutong Bai; Yu Diao; Lu Gan; Zhizheng Zhuo; Zixiao Yin; Tianqi Hu; Dan Cheng; Hutao Xie; Delong Wu; Houyou Fan; Quan Zhang; Yunyun Duan; Fangang Meng; Yaou Liu; Yin Jiang; Jianguo Zhang
Journal:  Front Aging Neurosci       Date:  2022-03-21       Impact factor: 5.750

9.  Functional Brain Connectivity Patterns Associated with Visual Hallucinations in Dementia with Lewy Bodies.

Authors:  Stefania Pezzoli; Matteo De Marco; Giovanni Zorzi; Annachiara Cagnin; Annalena Venneri
Journal:  J Alzheimers Dis Rep       Date:  2021-04-29

10.  Classification of Alzheimer's Disease Based on Abnormal Hippocampal Functional Connectivity and Machine Learning.

Authors:  Qixiao Zhu; Yonghui Wang; Chuanjun Zhuo; Qunxing Xu; Yuan Yao; Zhuyun Liu; Yi Li; Zhao Sun; Jian Wang; Ming Lv; Qiang Wu; Dawei Wang
Journal:  Front Aging Neurosci       Date:  2022-02-22       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.